CompletedNo phase
Inspire Singapore Study
Key facts
- Who runs it
- Inspire Medical Systems, Inc.
- Where
- Singapore2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 44 people enrolled
- Started
- 25 Jul 2024
- Ended
- 1 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Inspire System
- Record updated
- 22 May 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Other criteria
- Main Inclusion Criteria:
- Diagnosis of moderate to severe OSA (AHI 15-65)
- Failure of, or intolerance to CPAP; Main Exclusion Criteria:
- Central + mixed apneas > 25% of total AHI
- Presence of complete concentric collapse (CCC)
- Compromised neurological control of the upper airway; Other eligibility criteria may apply
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Prospective, multicenter, open-label study designed to confirm device performance of Inspire system in Singapore.
The group in the trial
- Hypoglossal nerve stimulationOther group
Treatment: Inspire System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Inspire Singapore Study: Confirmation of Therapy Performance
- Record updated
- 22 May 2026